Posts tagged Anaplastic lymphoma kinase rearrangement (ALK rearrangement)
Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report
Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi. READ ARTICLE

Annuals of Translational Medicine DOI:10.21037/atm.2019.01.24

Authors: Laura Bender, Guillaume Meyer, Elisabeth Quoix and Bertrand Mennecier

Read More
Case StudyKirk SmithAnaplastic lymphoma kinase rearrangement (ALK rearrangement), ceritinib, diffuse interstitial pneumonitis, non-small cell lung cancer (NSCLC)